Skip to main content
. 2020 Jul 22;9(5):596–612. doi: 10.1159/000508809

Table 4.

OS in high-burden intermediate-stage HCC patients who achieved durable response ≥3 and ≥6 months (Child-Pugh A)

OS, months 95% CI p value
Model 1

Group A
Durable response ≥3 months
 Present 47.7 40.7–54.7 <0.001
 Absent 21.8 15.6–28.0
Durable response ≥6 months
 Present 68.4 undefined <0.001
 Absent 26.7 22.5–31.0

Group A + B
Durable response ≥3 months
 Present 47.7 42.6–52.8 <0.001
 Absent 20.0 15.0–25.0
Durable response ≥6 months
 Present 68.5 undefined <0.001
 Absent 25.0 20.7–29.3

Model 2

Group A
Durable response ≥3 months
 Present 32.4 25.3–39.6 0.014
 Absent 16.5 11.4–21.7
Durable response ≥6 months
 Present 41.6 19.5–63.6 0.057
 Absent 22.2 15.3–29.1

Group A + B
Durable response ≥3 months
 Present 36.3 23.5–49.1 <0.001
 Absent 15.5 12.2–18.8
Durable response ≥6 months
 Present 47.7 36.8–58.6 0.005
 Absent 21.0 16.3–25.6

Model 3

Group A
Durable response ≥3 months
 Present 32.4 26.0–38.9 0.008
 Absent 15.1 13.0–17.3
Durable response ≥6 months
 Present 41.6 16.4–66.7 0.079
 Absent 20.1 14.9–27.0

Group A + B
Durable response ≥3 months
 Present 36.3 24.7–47.9 <0.001
 Absent 15.2 13.6–16.8
Durable response ≥6 months
 Present 50.8 28.7–72.9 0.007
 Absent 20.0 14.4–25.6

CI, confidence interval; HCC, hepatocellular carcinoma; OS, overall survival.